Omeprazole

Major

Omeprazole Fluconazole Diflucan Explained Increased omeprazole exposure Details Omeprazole Fosnetupitant Explained Increased exposure of CYP3A4 substrate Details Omeprazole Fosphenytoin Cerebyx Explained Increased phenytoin exposure or fosphenytoin (prodrug of phenytoin), an increased risk of phenytoin or fosphenytoin toxicity (atax... Details Omeprazole Gefitinib Iressa Decreased exposure of gefitinib Details Omeprazole Indinavir Explained Reduced indinavir exposure with reduced efficacy Details Omeprazole Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Omeprazole Itraconazole Sporanox Explained Reduced itraconazole exposure, increased omeprazole exposure and an increased risk of omeprazole-related adverse effects Details Omeprazole Ketoconazole Extina Explained Reduced ketoconazole exposure, reduced efficacy of ketoconazole, increased omeprazole exposure and an increased risk of omeprazole... Details Omeprazole Ledipasvir Explained Decreased ledipasvir exposure and loss of efficacy Details Omeprazole Letermovir Prevymis Explained Altered omeprazole exposure Details Omeprazole Levoketoconazole Recorlev Explained Reduced levoketoconazole exposure Details Omeprazole Lisdexamfetamine Arynta Explained Increased exposure to amphetamine Details Omeprazole Lonafarnib Zokinvy Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Omeprazole Mavacamten Camzyos Explained Increased mavacamten exposure, an increased risk of mavacamten-related adverse reactions, reduced omeprazole exposure and reduced... Details Omeprazole Methadone Diskets Explained Increased methadone exposure and an increased risk of opioid adverse effects Details Omeprazole Methamphetamine Desoxyn Explained Increased exposure to amphetamine Details Omeprazole Methotrexate Jylamvo Increased methotrexate exposure and an increased risk of methotrexate toxicity Details Omeprazole Methylphenidate Adhansia XR® Altered pharmacodynamic and changes in release profile of methylphenidate Details Omeprazole Mifepristone Korlym Explained Increased CYP3A4 substrate exposure Details Omeprazole Mycophenolate Mofetil Explained Reduced mycophenolic acid exposure Details Omeprazole Nelfinavir Viracept Explained Increased omeprazole exposure, altered nelfinavir exposure and reduced efficacy of nelfinavir Details Omeprazole Neratinib Nerlynx Decreased neratinib solubility, absorption, and exposure Details Omeprazole Netupitant Explained Increased exposure of CYP3A4 substrate Details Omeprazole Nilotinib Explained Reduced nilotinib exposure and reduced efficacy of nilotinib Details Omeprazole Nirogacestat Ogsiveo Explained Reduced nirogacestat/CYP2C19 substrate exposure and reduced efficacy of nirogacestat/CYP2C19 substrate Details Omeprazole Nivolumab Opdivo Explained Reduced efficacy of nivolumab Details Omeprazole Octreotide Bynfezia Decreased octreotide bioavailability Details Omeprazole Olanzapine Explained Reduced OLANZapine exposure and reduced efficacy of OLANZapine Details Omeprazole Omaveloxolone Skyclarys Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Omeprazole Ombitasvir Explained Increased ombitasvir concentration and decreased omeprazole concentration Details Omeprazole Palbociclib Ibrance Explained Reduced efficacy of palbociclib Details Omeprazole Paltusotine Palsonify Explained Reduced paltusotine exposure and reduced efficacy of paltusotine Details Omeprazole Paritaprevir Explained Increased paritaprevir exposure; decreased omeprazole exposure Details Omeprazole Pazopanib Votrient Explained Reduction in pazopanib bioavailability Details Omeprazole Pexidartinib Turalio Explained Reduced pexidartinib exposure Details Omeprazole Phenobarbital Fidoquel Explained Reduced omeprazole exposure, reduced efficacy of omeprazole, increased PHENobarbital exposure and an increased risk of PHENobarbit... Details Omeprazole Phenytoin Dilantin Explained Increased phenytoin exposure or fosphenytoin (prodrug of phenytoin), an increased risk of phenytoin or fosphenytoin toxicity (atax... Details Omeprazole Pirtobrutinib Jaypirca Explained Increased sensitive CYP2C19 substrate exposure and an increased risk of sensitive CYP2C19 substrate-related adverse effects Details Omeprazole Posaconazole Noxafil Explained Increased omeprazole exposure and reduced posaconazole exposure Details Omeprazole Primidone Mysoline Explained Reduced omeprazole exposure, reduced efficacy of omeprazole, increased PHENobarbital exposure and an increased risk of PHENobarbit... Details